Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Haemonetics Corporation
HAE
NYSE·Healthcare·Medical - Instruments & Supplies·Mkt cap $3.4B
$72.96
▼ -2.53%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$47.32 - $87.32
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 1.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary automated collection and analysis technologies with high switching costs and regulatory barriers
- Integrated software platforms (NexLynk DMS, SafeTrace Tx, BloodTrack, TEG Manager) creating ecosystem lock-in across customer operations
- Decades of R&D expertise and FDA-cleared portfolio serving mission-critical blood management and hemostasis assessment applications
Bear Case
1 risk
- Low volatility (beta 0.5).
Growth
Stable outlook
Rising global demand for plasma-derived therapies and increased plasma donation center expansion
Value
Attractively priced below Medical Devices peer average
Momentum
Hot
+31.7% over 3m
Quality
Strong
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying HAE right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 6, 2026
MAY 7, 2026
Reported EPS of $1.29 vs $1.28 consensus (+0.8% surprise). Revenue of $346.4M vs $336.8M expected (+2.8%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+0.8%
Next: May 6, 2026
Revenue trend · last 8Q
—
—
—
+4%
-4%
-4%
-5%
-3%
Q4 24
Q1 24
Q2 24
Q3 24
Q4 25
Q1 25
Q2 25
Q3 25
$343.3M
$336.2M
$345.5M
$348.5M
$330.6M
$321.4M
$327.3M
$339.0M
Margins · last 8Q
Gross
56.5%
Operating
20.5%
Profit
13.2%
Wall Street consensus
6 analysts · 67% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
67%
Hold
33%
Sell
0%
Median Price Target
$70.00
▼ -4.1% vs $72.96
Latest: Citi · May 28, 2026
3 analysts covering